Reader TTS

Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away.

After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile,

here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …

Sanofi and Regeneron Pharmaceuticals filed a lawsuit seeking to preempt a possible patent challenge from Amgen over their forthcoming Dupixent drug for atopic dermatitis. The companies want

a court order declaring the drug, which the Food and Drug Administration is expected to be approve shortly, does not infringe on an Amgen patent for a failed asthma treatment. The suit comes

two months after another court blocked Sanofi and Regeneron from selling their Praluent cholesterol drug after losing a patent infringement case to Amgen. But Praulent remains on the market

during an appeal.

A Novartis heart failure drug called serelaxin failed in a late-stage trial, casting major doubts over a treatment once seen as a potential blockbuster, Pharmaphorum informs us. At one

point, analysts expected serelaxin sales could exceed $2 billion, but this appears increasingly unlikely, since the medicine had already been rejected three years ago by regulators in the US

and EU. Leerink analyst Seamus Fernandez said the trial was a “long shot.”